NASDAQ:ARDM - Aradigm Stock Price, Price Target & More

Get Started

$1.32 -0.02 (-1.49 %)

(As of 05/24/2018 01:25 PM ET)

Previous Close$1.34

Today's Range$1.32 - $1.34

52-Week Range$1.03 - $7.35

Volume300 shs

Average Volume49,602 shs

Market Capitalization$19.77 million

P/E Ratio-1.86

Dividend YieldN/A

Beta0.89

About Aradigm (NASDAQ:ARDM)

Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. Its lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis, cystic fibrosis, and non-tuberculosis mycobacterium. The company is also developing inhaled ciprofloxacin formulations for treatment of patients with cystic fibrosis, and has tested for the prevention and treatment of inhaled bioterrorism infections, such as Coxiella burnetii or Q fever, inhalation anthrax, tularemia, melioidosis and pneumonic plague. Aradigm Corporation has collaboration agreements with Grifols, S.A. The company was founded in 1991 and is headquartered in Hayward, California.

Receive ARDM News and Ratings via Email

Sign-up to receive the latest news and ratings for ARDM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:ARDM

CUSIPN/A

Webwww.aradigm.com

Phone510-265-9000

Debt

Debt-to-Equity Ratio-0.93

Current Ratio0.60

Quick Ratio0.60

Price-To-Earnings

Trailing P/E Ratio-1.86

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$14.47 million

Price / Sales1.39

Cash FlowN/A

Price / CashN/A

Book Value($1.10) per share

Price / Book-1.20

Profitability

EPS (Most Recent Fiscal Year)($0.72)

Net Income$-10,700,000.00

Net Margins-83.04%

Return on EquityN/A

Return on Assets-125.01%

Miscellaneous

Employees23

Outstanding Shares15,210,000

Aradigm (NASDAQ:ARDM) Frequently Asked Questions

What is Aradigm's stock symbol?

Aradigm trades on the NASDAQ under the ticker symbol "ARDM."

How were Aradigm's earnings last quarter?

Aradigm Co. (NASDAQ:ARDM) issued its quarterly earnings results on Tuesday, May, 15th. The company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.10. The company earned $1.47 million during the quarter. View Aradigm's Earnings History.

When is Aradigm's next earnings date?

Aradigm is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Aradigm.

What price target have analysts set for ARDM?

1 brokers have issued 12-month price objectives for Aradigm's stock. Their forecasts range from $10.00 to $10.00. On average, they expect Aradigm's stock price to reach $10.00 in the next year. View Analyst Ratings for Aradigm.

Who are some of Aradigm's key competitors?

Some companies that are related to Aradigm include Edap Tms (EDAP), Semler Scientific (SMLR), BioSig Technologies (BSGM), Viveve Medical (VIVE), Stereotaxis (STXS), Soleno Therapeutics (SLNO), Digirad (DRAD), Dynatronics (DYNT), Nexeon MedSystems (NXNN), CHF Solutions (CHFS), Reshape Lifesciences (RSLS), FC Global Realty (FCRE), Non-Invasive Monitoring System (NIMU), Vasomedical (VASO) and Endra (NDRA).

Who are Aradigm's key executives?

Aradigm's management team includes the folowing people:

Dr. John M. Siebert, Exec. Chairman, Interim Principal Exec. Officer & Acting Principal Financial Officer (Age 78)
Dr. David Cipolla Ph.D., VP of Preclinical R&D

Has Aradigm been receiving favorable news coverage?

Headlines about ARDM stock have been trending somewhat positive this week, Accern reports. The research group ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aradigm earned a media sentiment score of 0.15 on Accern's scale. They also assigned headlines about the company an impact score of 46.05 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Aradigm's major shareholders?

Aradigm's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FIRST EAGLE INVESTMENT MANAGEMENT, LLC (26.31%), FIRST EAGLE INVESTMENT MANAGEMENT, LLC (26.31%), First Eagle Investment Management LLC (22.25%) and Arnhold LLC (3.15%). View Institutional Ownership Trends for Aradigm.

Which institutional investors are selling Aradigm stock?

ARDM stock was sold by a variety of institutional investors in the last quarter, including First Eagle Investment Management LLC. View Insider Buying and Selling for Aradigm.

Which institutional investors are buying Aradigm stock?

ARDM stock was acquired by a variety of institutional investors in the last quarter, including Arnhold LLC. View Insider Buying and Selling for Aradigm.

How do I buy shares of Aradigm?

Shares of ARDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aradigm's stock price today?

One share of ARDM stock can currently be purchased for approximately $1.32.

How big of a company is Aradigm?

Aradigm has a market capitalization of $19.77 million and generates $14.47 million in revenue each year. The company earns $-10,700,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Aradigm employs 23 workers across the globe.

How can I contact Aradigm?

Aradigm's mailing address is 3929 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at 510-265-9000 or via email at [email protected]

MarketBeat Community Rating for Aradigm (ARDM)

Community Ranking:		1.7 out of 5 ()
Outperform Votes:		93 (Vote Outperform)
Underperform Votes:		185 (Vote Underperform)
Total Votes:		278

MarketBeat's community ratings are surveys of what our community members think about Aradigm and other stocks. Vote "Outperform" if you believe ARDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Aradigm (NASDAQ:ARDM) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

1 Wall Street analysts have issued ratings and price targets for Aradigm in the last 12 months. Their average twelve-month price target is $10.00, suggesting that the stock has a possible upside of 657.58%. The high price target for ARDM is $10.00 and the low price target for ARDM is $10.00. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Buy
Consensus Rating Score:	2.00	2.00	2.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$10.00	$10.00	$10.00	$10.00
Price Target Upside:	657.58% upside	160.42% upside	160.42% upside	295.26% upside

Aradigm (NASDAQ:ARDM) Consensus Price Target History

Price Target History for Aradigm (NASDAQ:ARDM)

Aradigm (NASDAQ:ARDM) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
1/12/2018	Ladenburg Thalmann	Downgrade	Buy ➝ Neutral		High

(Data available from 5/24/2016 forward)

Aradigm (NASDAQ:ARDM) Earnings History and Estimates Chart

Earnings by Quarter for Aradigm (NASDAQ:ARDM)

Aradigm (NASDAQ:ARDM) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.07 EPS

Aradigm (NASDAQ ARDM) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/8/2018		($0.22)					N/A
5/15/2018	Q1 2018	($0.42)	($0.32)		$1.47 million	View	N/A
3/29/2018	Q4 2017	($0.36)	($0.28)		$2.37 million	View	N/A
11/2/2017	Q3 2017	($0.31)	($0.26)		$2.73 million	View	N/A
8/10/2017	Q2 2017	($0.30)	$0.07		$7.68 million	View	N/A
5/15/2017	Q1 2017	($0.43)	($0.2490)		$1.69 million	View	N/A
3/28/2017	Q4 2016	($0.37)	($0.54)		$0.13 million	View	N/A
11/9/2016	Q3 2016	($0.53)	($0.55)		$0.05 million	View	N/A
8/10/2016	Q2	($0.59)	($0.59)		$0.01 million	View	N/A
5/10/2016	Q1	($0.59)	($0.55)		$0.01 million	View	N/A
3/15/2016	Q415	($0.55)	($0.63)		$0.04 million	View	N/A
11/11/2015	Q3	($0.19)	($0.38)		$4.67 million	View	N/A
8/13/2015	Q2	($0.08)	($0.08)	$11.60 million	$10.00 million	View	N/A
5/11/2015	Q1	($0.06)	($0.08)		$8.77 million	View	N/A
3/17/2015	Q414	($0.07)	($0.06)	$6.70 million	$8.10 million	View	N/A
11/7/2014	Q314	($0.10)	($0.06)	$4.80 million	$6.60 million	View	N/A
8/7/2014	Q214	($0.09)	($0.09)	$4.25 million	$12.20 million	View	N/A
5/14/2014	Q1 2014		$0.40		$6.63 million	View	N/A
10/28/2013	Q3 13		($0.04)		$4.55 million	View	N/A
8/8/2013	Q2 2013		($0.40)		$0.25 million	View	N/A
5/14/2013	Q1 2013		($0.40)		$0.28 million	View	N/A
3/26/2013	Q4 2012		($0.40)			View	N/A
11/8/2012	Q3 2012	($0.40)	($0.40)			View	N/A
8/9/2012	Q2 2012	($0.40)	($0.36)			View	N/A
5/11/2012	Q1 2012	($0.40)	($0.40)			View	N/A
3/27/2012	Q4 2011	($0.40)	($0.32)			View	N/A
11/10/2011	Q3 2011	($0.80)	($0.52)			View	N/A
8/9/2011	Q2 2011	($0.80)	($0.68)			View	N/A
5/12/2011	Q1 2011	($0.80)	($0.56)			View	N/A
3/24/2011	Q4 2010		($0.56)			View	N/A
11/11/2010	Q3 2010	($1.20)	($0.88)			View	N/A
8/12/2010	Q2 2010	($2.00)	($1.56)			View	N/A
5/13/2010	Q1 2010		($0.08)			View	N/A
3/23/2010	Q4 2009	($0.80)	($1.36)			View	N/A
11/5/2009	Q3 2009	($1.20)	$0.40			View	N/A
8/6/2009	Q2 2009	($2.00)	($1.76)			View	N/A
5/12/2009	Q1 2009	($3.60)	($2.96)			View	N/A
3/25/2009	Q4 2008	($5.20)	($3.92)			View	N/A
11/12/2008	Q3 2008	($5.20)	($3.36)			View	N/A
8/8/2008	Q2 2008	($4.80)	($5.20)			View	N/A
3/25/2008	Q4 2007	($4.00)	($5.36)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Aradigm (NASDAQ:ARDM) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Aradigm (NASDAQ ARDM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.50%
Institutional Ownership Percentage: 30.28%

Insider Trading History for Aradigm (NASDAQ:ARDM)

Institutional Ownership by Quarter for Aradigm (NASDAQ:ARDM)

Aradigm (NASDAQ ARDM) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/29/2018	Juergen Kurt Froehlich	Insider	Sell	17,011	$1.53	$26,026.83	90,853
4/4/2017	Juergen Kurt Froehlich	Insider	Sell	3,765	$1.51	$5,685.15	85,129
10/4/2016	Juergen Kurt Froehlich	Insider	Sell	423	$6.76	$2,859.48	88,894
6/21/2016	Juergen Kurt Froehlich	Insider	Sell	333	$4.45	$1,481.85
12/13/2013	Virgil Thompson	Director	Sell	3,340	$0.17	$567.80
8/27/2013	First Eagle Investment Managem	Major Shareholder	Buy	40,322,580	$0.12	$4,838,709.60
12/11/2012	First Eagle Investment Managem	Major Shareholder	Buy	41,666,667	$0.12	$5,000,000.04

(Data available from 1/1/2013 forward)

Aradigm (NASDAQ ARDM) News Headlines

Source:

Date	Headline
	Aradigm (ARDM) Issues Quarterly Earnings Results www.americanbankingnews.com - May 16 at 1:58 PM
	Contrasting Aradigm (ARDM) and Varian Medical Systems (VAR) www.americanbankingnews.com - May 15 at 1:42 PM
	Aradigm: 1Q Earnings Snapshot finance.yahoo.com - May 15 at 8:27 AM
	Aradigm Announces First Quarter 2018 Financial Results finance.yahoo.com - May 15 at 8:27 AM
	EnteroMedics (RSLS) and Aradigm (ARDM) Head to Head Analysis www.americanbankingnews.com - April 26 at 11:32 AM
	Juniper Pharmaceuticals: Undervalued With Double-Digit Revenue Growth seekingalpha.com - April 19 at 5:40 PM
	CHEK On Watch, ARQL Inks A Deal, RTTR To Move RP-G28 Into Phase III www.finanznachrichten.de - April 18 at 8:16 AM
	Aradigm (ARDM) versus Helius Medical Technologies (HSDT) Financial Review www.americanbankingnews.com - April 15 at 5:18 PM
	Aradigm (ARDM) Lowered to Sell at Zacks Investment Research www.americanbankingnews.com - April 13 at 5:29 PM
	Aradigm (ARDM) Upgraded to "Buy" at Zacks Investment Research www.americanbankingnews.com - April 9 at 11:59 PM
	Wired News – EMA Completed Validation of MAA for Aradigm’s Linhaliq in Non-Cystic Fibrosis Bronchiectasis finance.yahoo.com - April 9 at 8:18 AM
	BRIEF-Aradigm Announces EMA Has Completed Its Validation Of The MAA Submission www.reuters.com - April 6 at 5:42 PM
	Aradigm Corp. (ARDM) Announces EMA Has Completed Its Validation of MAA Submission www.streetinsider.com - April 5 at 5:18 PM
	EMA accepts Aradigm's marketing application for Linhaliq for certain lung infections; shares ahead 9% seekingalpha.com - April 5 at 10:31 AM
	Aradigm (ARDM) Receives Average Rating of "Hold" from Brokerages www.americanbankingnews.com - April 1 at 1:26 AM
	Aradigm net loss improves in Q4 seekingalpha.com - March 24 at 5:15 PM
	Aradigm (ARDM) Posts Earnings Results, Misses Estimates By $0.03 EPS www.americanbankingnews.com - March 24 at 1:24 PM
	BRIEF-Aradigm Reports Q4 Loss Per Share Of $0.28 www.reuters.com - March 23 at 5:42 PM
	Zacks Investment Research Upgrades Aradigm (ARDM) to Hold www.americanbankingnews.com - March 19 at 5:34 PM
	Aradigm (ARDM) to Release Quarterly Earnings on Monday www.americanbankingnews.com - March 19 at 1:12 AM
	Glancy Prongay & Murray LLP Reminds Investors of the March 12, 2018 Deadline in the Class Action Lawsuit Against Aradigm Corporation finance.yahoo.com - March 12 at 6:40 PM
	FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Aradigm Corporation (ARDM) & Lead Plaintiff Deadline: March 12, 2018 finance.yahoo.com - March 12 at 6:40 PM
	DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Aradigm Corporation And Reminds Investors With Losses To Contact The Firm finance.yahoo.com - March 12 at 6:40 PM
	DEADLINE REMINDER NOTICE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Aradigm Corporation And Reminds Investors With Losses To Contact The Firm finance.yahoo.com - March 10 at 6:24 PM
	March 12th Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aradigm Corporation (ARDM) finance.yahoo.com - March 10 at 6:24 PM
	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Aradigm Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 12, 2018 - ARDM finance.yahoo.com - March 10 at 6:24 PM
	MONDAY DEADLINE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Aradigm Corporation And Reminds Investors With Losses To Contact The Firm finance.yahoo.com - March 10 at 6:24 PM
	MONDAY DEADLINE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Aradigm Corporation finance.yahoo.com - March 8 at 6:45 PM
	Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Aradigm Corporation Investors (ARDM) finance.yahoo.com - March 8 at 6:45 PM
	ARDM EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Aradigm Corporation and a Lead Plaintiff Deadline of March 12, 2018 finance.yahoo.com - March 8 at 6:45 PM
	5-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Aradigm Corporation finance.yahoo.com - March 7 at 6:35 PM
	DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Aradigm Corporation (ARDM) & Lead Plaintiff Deadline: March 12, 2018 finance.yahoo.com - March 7 at 6:35 PM
	IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Aradigm Corporation finance.yahoo.com - March 6 at 8:15 AM
	EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Aradigm Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 12, 2018 – ARDM finance.yahoo.com - March 5 at 5:50 PM
	FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Aradigm Corporation to Contact the Firm finance.yahoo.com - March 3 at 8:16 AM
	The Klein Law Firm Reminds Shareholders of Aradigm Corporation of Commencement of a Class Action and a Lead Plaintiff Deadline of March 12, 2018 (ARDM) finance.yahoo.com - March 2 at 6:11 PM
	DEADLINE APPROACHING: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Aradigm Corporation finance.yahoo.com - March 2 at 6:11 PM
	Aradigm: Points Of Discussion seekingalpha.com - March 1 at 5:52 PM
	MARCH 12 DEADLINE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Aradigm Corporation finance.yahoo.com - March 1 at 5:52 PM
	ARDM SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Aradigm Corporation and a Lead Plaintiff Deadline of March 12, 2018 finance.yahoo.com - March 1 at 5:52 PM
	ARADIGM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aradigm Corporation To Contact The Firm finance.yahoo.com - February 28 at 8:17 AM
	The Klein Law Firm Reminds Investors in Aradigm Corporation of a Class Action and a Lead Plaintiff Deadline of March 12, 2018 (ARDM) finance.yahoo.com - February 26 at 5:45 PM
	Glancy Prongay & Murray LLP Continues Investigation on Behalf of Aradigm Corporation Investors (ARDM) finance.yahoo.com - February 26 at 5:45 PM
	INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Aradigm Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 12, 2018 - ARDM finance.yahoo.com - February 23 at 5:59 PM
	Pawar Law Group Reminds Aradigm Corporation Investors of Important March 12, 2018 Lead Plaintiff Deadline in Class Action - ARDM finance.yahoo.com - February 21 at 5:27 PM
	INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Aradigm Corporation (ARDM) & Lead Plaintiff Deadline: March 12, 2018 finance.yahoo.com - February 21 at 8:21 AM
	Can Aradigm Corporation (NASDAQ:ARDM) Improve Your Portfolio Returns? finance.yahoo.com - February 20 at 5:47 PM
	ARDM NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Aradigm Corporation -- ARDM finance.yahoo.com - February 19 at 5:10 PM
	The Klein Law Firm Reminds Shareholders of Aradigm Corporation of a Class Action and a Lead Plaintiff Deadline of March 12, 2018 (ARDM) finance.yahoo.com - February 15 at 5:21 PM
	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aradigm Corporation of Class Action Lawsuit and Upcoming Deadline – ARDM finance.yahoo.com - February 15 at 9:30 AM

Aradigm (NASDAQ:ARDM) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Aradigm (NASDAQ:ARDM) Income Statement, Balance Sheet and Cash Flow Statement

Aradigm (NASDAQ ARDM) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff